Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3967323 | 0.98 | IDO1 (0.46) | SLC6A4SLC6A3TSHRMAOAMAOB | |
| SCHEMBL1822033 | 0.98 | MAOB (0.47) | SLC6A4SLC6A3TSHRMAOAMAOB | |
| Hydrochloric Acid SCHEMBL3966019 | 0.96 | IDO1 (0.47) | SLC6A4SLC6A3TSHRMAOAMAOB | |
| SCHEMBL4868046 | 0.92 | TDP1 (0.52) | SLC6A4SLC6A3TSHRMAOAMAOB | |
| SCHEMBL1824702 | 0.91 | MAOB (0.55) | SLC6A4TSHRMAOAMAOBIDO1 | |
| SCHEMBL1820761 | 0.83 | TSHR (0.50) | SLC6A4SLC6A3TSHRMAOBIDO1 | |
| SCHEMBL4868053 | 0.82 | GAA (0.37) | TSHRMAOAMAOBIDO1AGXT | |
| Hydrochloric Acid SCHEMBL3964945 | 0.81 | TSHR (0.49) | SLC6A4SLC6A3TSHRMAOBIDO1 | |
| SCHEMBL2371058 | 0.81 | TAAR1 (0.52) | SLC6A4SLC6A3TSHRMAOBIDO1 | |
| SCHEMBL31304814 | 0.80 | TSHR (0.47) | SLC6A4SLC6A3TSHRIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761509-B1 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7563806-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1595873-A1 | Substituted cycloalkyl derivatives for the treatment of respiratory diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | CHRM1, CHRM2, CHRM3 | SLC6A4 4448/4885SLC6A3 4799/4885TSHR 2041/4885 |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | CHRM1, CHRM2, CHRM3 | SLC6A4 4448/4885SLC6A3 4799/4885TSHR 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.